Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several ...

In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of ...

A new Phase 1 clinical trial for the huntingtin-lowering drug ALN-HTT02 was initiated this week with the first dose given.

Advanced Care Planning is a tool that can allow people living with Huntington’s disease to compassionately engage with loved ...

At this time of giving, we want to give thanks to you, the Huntington’s disease (HD) community, for all you have done for HD ...